Venous stent versus conventional stent for the treatment of central vein obstruction in hemodialysis patients: a retrospective study

2021 ◽  
pp. 028418512110051
Author(s):  
Surasit Akkakrisee ◽  
Keerati Hongsakul
Keyword(s):  
Endovascular Treatment ◽  
Patency Rate ◽  
Demographic Data ◽  
Hemodialysis Patients ◽  
Primary Patency ◽  
Central Vein ◽  
Primary Patency Rate ◽  
Patient Demographic Data ◽  
Upper Thoracic ◽  
Vein Stenosis

Background Endovascular treatment is a first-line treatment for upper thoracic central vein obstruction (CVO). Few studies using bare venous stents (BVS) in CVO have been conducted. Purpose To evaluate the treatment performance of upper thoracic central vein stenosis between BVS and conventional bare stent (CBS) in hemodialysis patients. Methods Hemodialysis patients with upper thoracic central vein obstruction who underwent endovascular treatment at the interventional unit of our institution from 1 January 2008 to 31 December 2018 were enrolled in the present study. CBS was used to treat central vein obstruction in 43 patients and BVS in 34 patients. We compared the primary patency rates and complications between the two stent types. P values < 0.05 were considered statistically significant. Results The patient demographic data between the CBS and BVS groups were similar. The characteristics of the lesions, procedures, and complications were not significantly different between the two groups ( P > 0.05). There were no statistically significant differences of primary patency rates at three and six months between the BVS and CBS groups (94.1% vs. 86.0% and 73.5% vs. 58.1%, respectively; P > 0.05). The primary patency rate at 12 months in the BVS group was significantly higher than that in the CBS group (61.8% vs. 32.6%; P = 0.008). Conclusion Endovascular treatment of central vein obstruction with BVS provided a higher primary patency rate at 12 months than CBS.

Primary Patency Rate of Arteriovenous Fistula Created for Hemodialysis Patients: The Indonesian Experience

2018 ◽  
Vol 23 (4) ◽  
pp. 229-233 ◽  
Author(s):  
Yanto Sandy Tjang ◽  
Glenn Joshua Sumadi
Keyword(s):  
Arteriovenous Fistula ◽  
Patency Rate ◽  
Surgical Techniques ◽  
Hemodialysis Patients ◽  
Primary Patency ◽  
Current Data ◽  
Rank Test ◽  
Primary Patency Rate ◽  
Female Patients ◽  
Kaplan Meier

Abstract Introduction: Clinical practice guidelines endorse the arteriovenous fistula as the preferred form of vascular access. Concerns have been raised regarding its high risk of primary failure. Its estimated primary patency rate varies in the literature. Since most of the current data are from Western countries and information from the developing countries is scarce, we aim to evaluate the primary patency rate of arteriovenous fistula created for hemodialysis patients in our hospital. Methodology: We analyzed data from all patients undergoing the creation of arteriovenous fistula for hemodialysis at the PGI Hospital Cikini in Jakarta, Indonesia, from January to December 2015. Information needed was retrieved from the medical records. Actuarial patency rate was created by the Kaplan-Meier product-limit method. Differences between curves were compared by means of a log-rank test. Results: A total of 253 arteriovenous fistula in the upper arm were created in patients requiring hemodialysis. The overall 6-, 12-, and 18-month primary patency rates of arteriovenous fistula created for hemodialysis patients were 88%, 85%, and 79%, respectively. There was a difference in primary patency rate of arteriovenous fistula by gender. The 6- and 12-month primary patency rates of arteriovenous fistula created for male hemodialysis patients were 92% and 89%; the rates for female patients were 81% and 78%, respectively (P = .027). Conclusions: Careful preoperative patient assessment, optimal surgical techniques, and adequate postoperative care play an important role for the favorable outcome. The primary patency rate in male hemodialysis patients was significantly higher than in female patients.

Endovascular treatment for chronic atherosclerotic occlusive mesenteric disease: Is stenting superior to balloon angioplasty?

VASA ◽  
2010 ◽  
Vol 39 (4) ◽  
pp. 319-324 ◽  
Author(s):  
Daliri ◽  
Grunwald ◽  
Jobst ◽  
Szucs-Farkas ◽  
Diehm ◽  
...  
Keyword(s):  
Endovascular Treatment ◽  
Patency Rate ◽  
Celiac Artery ◽  
Primary Patency ◽  
Secondary Patency ◽  
Chronic Mesenteric Ischemia ◽  
Primary Patency Rate ◽  
Secondary Patency Rate

Background: Endovascular treatment is an increasingly used therapeutic option in patients with chronic atherosclerotic occlusive mesenteric disease. Purpose of this study was evaluation of patency and mortality in patients treated with visceral artery percutaneous transluminal angioplasty (PTA) or stenting including follow-up. Patients and methods: A retrospective review of 17 consecutive patients (4 women, 13 men) with endovascular treatment for symptomatic chronic mesenteric ischemia from 1998 to 2004 was performed. Mean follow-up period was 42 months. Patient demographics, interventional details, primary and/or secondary patency and mortality were recorded. Cumulative mortality and patency rates were determined using Kaplan-Meier life table analysis. Results: Twenty-six interventions (PTA alone n = 13, PTA and stenting n = 13) were performed in 17 patients. Interventions were performed in the superior mesenteric artery (n = 13) and celiac artery (n = 13). The re-intervention rate was 30 % (6/26). Re-interventions were performed for the superior mesenteric artery (n = 4) and celiac artery (n = 2). Cumulative overall 1-year results were primary patency rate 81 %, secondary patency rate 94 %, and survival rate 82 %. Cumulative 10-year results were primary patency rate 73 %, secondary patency rate 94 %, and survival rate 65 %. The 10-year secondary patency rate was 100 % in patients post initial stenting and 86 % in patients post initial PTA. Conclusions: Long-term follow-up post endovascular treatment for chronic mesenteric ischemia demonstrated a considerable overall secondary patency rate of 94 %. However, the long-term secondary patency rate was higher in patients post initial stenting compared to PTA alone.

scholarly journals Efficacy of Endovascular Treatment of Central Vein Stenosis to Improve Vascular Access Performance in Hemodialysis Patients

2019 ◽  
Vol 58 (6) ◽  
pp. e186-e187
Author(s):  
Raffaella Mauro ◽  
Rodolfo Pini ◽  
Laura Maria Cacioppa ◽  
Mauro Gargiulo ◽  
Gianluca Faggioli ◽  
...  
Keyword(s):  
Endovascular Treatment ◽  
Vascular Access ◽  
Hemodialysis Patients ◽  
Central Vein ◽  
Vein Stenosis ◽  
Central Vein Stenosis

scholarly journals Study of endovascular treatment in obstructive aortoiliac lesions: Immediate and short-term results

2021 ◽  
Vol 0 (Ahead of Print) ◽  
Author(s):  
Dinesh Joshi ◽  
Tarun Madan ◽  
Riyaz Charaniya ◽  
Pratik Raval ◽  
Krutika Patel ◽  
...  
Keyword(s):  
Endovascular Treatment ◽  
Endovascular Therapy ◽  
Patency Rate ◽  
Demographic Data ◽  
Type A ◽  
Primary Patency ◽  
Occlusive Disease ◽  
Short Term ◽  
Stent Patency ◽  
Term Outcome

Objective: Aorto-iliac occlusive disease (AIOD) is a common atherosclerotic disease causing significant morbidity. Transatlantic intersociety consensus for the management of peripheral arterial disease (TASC II) recommends endovascular therapy (ET) for better management of patients with lesions type A and B. With the advent of endovascular therapy, type C and D lesions management is becoming more feasible with endovascular therapy than open surgery for aorto-iliac occlusive disease. We aimed to evaluate patients with AOID and to describe short-term outcome of endovascular treatment for such lesions. Methods: Patients with aorto-iliac occlusive diseases who underwent endovascular therapy were enrolled in the study. Their demographic data and risk factors were recorded. Patients were followed at 3 and 6 months and their primary patency rate and symptom status were recorded. Results: We enrolled 100 patients with a mean age of 59.77 (8.75) years with the majority of patients being male. The most common presentation was claudication (59%) followed by rest pain (31%) and gangrene (20%). The majority of patients had Transatlantic inter-society consensus (TASC) II type A (44%) and type B (31%) lesions; 15% of patients had types C lesions and the remaining 10% patients had type D lesions. Access site hematoma and contrast-induced nephropathy were present in 7% and 5% of patients respectively. Stent patency rate was 97% and 95% at 3 and 6 months follow up respectively. Conclusion:  Endovascular therapy in aorto-iliac occlusive disease is a safe, effective, and low-cost treatment option with a high patency rate and symptomatic improvement in the short-term.

Some Old Drugs Improve Late Primary Patency Rate of Native Arteriovenous Fistulas in Hemodialysis Patients

2009 ◽  
Vol 23 (4) ◽  
pp. 491-497 ◽  
Author(s):  
Marco Righetti ◽  
GianMichele Ferrario ◽  
Paola Serbelloni ◽  
Silvana Milani ◽  
Adalberto Tommasi
Keyword(s):  
Patency Rate ◽  
Hemodialysis Patients ◽  
Primary Patency ◽  
Primary Patency Rate ◽  
Arteriovenous Fistulas ◽  
Old Drugs

Self-Expanding Nitinol Stent vs Percutaneous Transluminal Angioplasty in the Treatment of Femoropopliteal Lesions: 3-Year Data From the SM-01 Trial

2019 ◽  
Vol 26 (2) ◽  
pp. 158-167 ◽  
Author(s):  
Osamu Iida ◽  
Kazushi Urasawa ◽  
Yasuo Komura ◽  
Yoshimitsu Soga ◽  
Naoto Inoue ◽  
...  
Keyword(s):  
Percutaneous Transluminal Angioplasty ◽  
Patency Rate ◽  
Velocity Ratio ◽  
Peak Systolic Velocity ◽  
Transluminal Angioplasty ◽  
Primary Patency ◽  
Stent Group ◽  
Primary Patency Rate ◽  
Multicenter Randomized Controlled Trial ◽  
Percutaneous Transluminal

Purpose: To report the midterm outcomes of a trial comparing self-expanding nitinol stents to percutaneous transluminal angioplasty (PTA) with provisional stenting in the treatment of obstructive disease in the superficial femoral and popliteal arteries. Materials and Methods: The SM-01 study ( ClinicalTrials.gov identifier NCT01183117), a single-blinded, multicenter, randomized controlled trial in Japan, enrolled 105 consecutive patients with de novo or postangioplasty restenotic femoropopliteal lesions; after removing protocol violations (1 from each group), 51 patients (mean age 74±8 years; 36 men) in the stent group and 52 patients (mean age 73±8 years; 35 men) in the PTA group were included in the intention-to-treat analysis. The groups were well-matched at baseline. Patients were followed to 36 months with duplex imaging. Three-year primary patency was assessed based on a duplex-derived peak systolic velocity ratio <2.5. Freedom from clinically-driven target vessel revascularization (TVR) and target lesions revascularization (TLR) were estimated using the Kaplan-Meier method. Results: The technical success rate was higher (100% vs 48%, p<0.001) and the frequency of vascular dissection was lower (4% vs 31%, p<0.001) in the stent group. The S.M.A.R.T stent group had a higher 3-year primary patency rate (73% vs 51%, p=0.033). Freedom from clinically-driven TVR and TLR were not significantly different between the groups. Conclusion: The S.M.A.R.T. stent maintained a higher primary patency rate than PTA at 3 years in this randomized trial; the need for clinically-driven revascularization was similar for both therapies.

Endovascular Treatment of Central Vein Stenoses and/or Occlusions in Hemodialysis Patients

2003 ◽  
Vol 26 (1) ◽  
pp. 27-30 ◽  
Author(s):  
Jana Maskov� ◽  
Jana Kom�rkov� ◽  
Ji?� Kiv�nek ◽  
Jan Danes ◽  
Marcela Slav�kov�
Keyword(s):  
Endovascular Treatment ◽  
Hemodialysis Patients ◽  
Central Vein

Transjugular percutaneous endovascular treatment of dysfunctional hemodialysis access

2018 ◽  
Vol 20 (5) ◽  
pp. 488-494 ◽  
Author(s):  
Jin Ho Kim ◽  
Sung Bum Cho ◽  
Yun Hwan Kim ◽  
Hwan Hoon Chung ◽  
Seung Hwa Lee ◽  
...  
Keyword(s):  
Endovascular Treatment ◽  
Internal Jugular Vein ◽  
Patency Rate ◽  
Jugular Vein ◽  
Hemodialysis Access ◽  
Procedure Time ◽  
Arteriovenous Fistulas ◽  
Arteriovenous Grafts ◽  
The Mean ◽  
Vein Stenosis

Purpose: To evaluate the feasibility and the outcomes of transjugular percutaneous endovascular treatment of dysfunctional hemodialysis access in patients with chronic kidney disease. Methods: A total of 50 transjugular treatments in 38 patients with arteriovenous fistulas or arteriovenous grafts from September 2011 to May 2015 were included in this study. Medical records and angiographies were retrospectively reviewed. Success rate, patency rate, procedure time, and complications including internal jugular vein stenosis were evaluated. Results: A total of 50 sessions of transjugular treatments were performed in 38 patients. There were 31 native arteriovenous fistulas including 10 immature cases and 19 arteriovenous grafts. Among the 50 cases, technical success was achieved in 45 and clinical success was achieved in 44; 37 cases (74%) with multiple stenotic sites were treated by the transjugular approach without placement of cross-sheaths. The mean time from puncture of the internal jugular vein to first fistulography was 10 min, and the mean total procedure time was 64 min. The primary patency rate at 6 months was 77%, while the secondary patency rate at 6 months was 97%. Perforation occurred in two cases during conventional percutaneous transluminal angioplasty after failure of the transjugular approach. One dissection occurred during the transjugular approach. There was no newly developed internal jugular vein stenosis during a mean follow-up period of 19.3 months. Conclusion: For the treatment of dysfunctional or immature hemodialysis access, the transjugular approach is a feasible and effective option that avoids injury to the graft or draining vein, especially in immature fistulas.

Relationship Between Postoperative Neutrophil–Lymphocyte Ratio and 6-Month Primary Patency of Percutaneous Transluminal Angioplasty in Femoropopliteal disease With Drug-Coated and Uncoated Balloons

Angiology ◽  
2018 ◽  
Vol 70 (3) ◽  
pp. 244-248 ◽  
Author(s):  
Yanhua Zhen ◽  
Zhihui Chang ◽  
Zhaoyu Liu ◽  
Jiahe Zheng
Keyword(s):  
Percutaneous Transluminal Angioplasty ◽  
Patency Rate ◽  
Transluminal Angioplasty ◽  
Primary Patency ◽  
Primary Patency Rate ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Logistic Analysis ◽  
Early Restenosis ◽  
Percutaneous Transluminal

We investigated the relationship of postoperative neutrophil–lymphocyte ratio (NLR) with 6-month primary patency of percutaneous transluminal angioplasty (PTA) in femoropopliteal disease using drug-coated balloon (DCB) or uncoated balloon (UCB). This retrospective study included 106 patients who received DCB (n = 44) or UCB (n = 62). The postoperative NLR was lower in the DCB group than that in the UCB group (2.60 vs 3.23; P = .004), and 6-month primary patency rate was significantly higher in DCB group than that in the UCB group (77.3% vs 53.2%; P = .011). Multivariate logistic analysis showed that the postoperative NLR was an independent predictor of 6-month primary patency after PTA in patients with femoropopliteal disease (odds ratio: 1.589, 95% confidence interval: 1.078-2.343; P = .019). The cutoff value of postoperative NLR was 3.05 for prediction of 6-month primary patency, with a sensitivity of 64.1% and specificity of 65.7%. The 6-month primary patency rate in the NLR ≤3.05 group was higher than that in the NLR >3.05 group (75.9% vs 47.9%; P = .003). In conclusion, DCB may improve early primary patency by inhibiting inflammation. A higher postoperative NLR was associated with early restenosis.

Sign in / Sign up

Export Citation Format

Share Document